Dulley, Frederico LuizSaboya, Rosaurade Moraes Hungria, Vãnia TietscheBueno, Nadjanara Dornade Mello, Fernando Gomes [UNESP]Frota, Maria TerezaChiattone, Carlos SergioBarros, José CarlosMori, Nair SumieSturaro, Danielde Almeida Macedo, Maria Cristina Martinsda Silva, Roberto Luizde Melo, Leila Maria Magalhães PessoaSouza, Cármino Antonio2014-05-272014-05-272005-11-01Sao Paulo Medical Journal, v. 123, n. 6, p. 266-270, 2005.1516-3180http://hdl.handle.net/11449/68477Context and Objective: Lipasomial daunorubicin has been used to treat hematological malignancies, including multiple myelomo (MM). The goal was to evaluate efficacy, side-effects and toxicity of liposomal daunorubicin and dexamethasone (DD Protocol). Design and Setting: Prospective study of Sírio-Libonês, São Camilo, Brasil and Alemão Oswaldo Cruz hospitals. Methods: Twenty consecutive patients with active MM received four cycles of liposomal daunorubicin intravenously for two hours (25-30 mg/m 2/day) on three consecutive days per month, with oral dexamethasone, (10 mg every six hours) on four consecutive days three times a month. Results: The male/female ratio was 1:1 and median age 60. Nine patients were stage IIA, ten IIIA and one IIIB. The median from diagnosis to starting DD was 13 months. All patients received four cycles, except one. Fifteen had already received chemotherapy before DD. Responses of > 50% reduction in serum monoclonal paraprotein were observed in six patients after first cycle (30%), six after second (30%) and four after third (20%), while four (20%) did not obtain this. Initially, 17 patients (85%) had anemia: 12 (70%) achieved correction. Progressive disease was observed in three patients (15%), while one had minimal response, four (20%) partial and 12 (60%) complete. Hemotologlical toxicity was acceptable: three patients (15%) had neutrophils < 1,000/mm 3; none had thrombocyfopenia. Gastrointestinal toxicity was mild: nausea (10%), anorexio (15%) and no vomiting. Conclusions: This treatment has mild toxicity and good response rate. It may therefore be feasible before autologous bone marraw transplantation.266-270engDaunorubicinDexamethasoneDrug theraphyDrug toxicityMultiple myelomableomycincyclophosphamidedaunorubicindexamethasonedoxorubicinliposomemelphalanparaproteinprednisonevincristineadultagedalopeciaanemiaanorexiaastheniaautologous bone marrow transplantationBrazilcancer combination chemotherapycancer growthcancer stagingcardiotoxicityclinical articleclinical trialcontrolled clinical trialcontrolled studydose responsedrug efficacydrug fatalitydrug responsedrug safetyfeasibility studyfemalegastrointestinal symptomhematologic malignancyhumanmalemultiple myelomanauseaneutropeniapneumoniaprospective studyprotein blood levelthrombocytopeniaurinary tract infectionvomitingAdultAgedAntineoplastic Combined Chemotherapy ProtocolsDrug Administration ScheduleFemaleHumansLiposomesMaleMiddle AgedMultiple MyelomaParaproteinsProspective StudiesTreatment OutcomeArtigo10.1590/S1516-31802005000600003S1516-31802005000600003Acesso aberto2-s2.0-337500469372-s2.0-33750046937.pdf